

Seasonal Surge Lifts Offtake, Yet Surplus Signals Underlying Strain

Fertilizer Uptick Masks YTD Weakness


With the Kharif 2025 season in full stride, fertilizer demand saw a notable resurgence in May, buoyed by improved water availability and the activation of credit facilities via the Kissan Card scheme. Total nutrient offtake jumped 27% y/y to 311kt, driven by a 17% rise in nitrogen and a 108% surge in phosphate. Urea volumes grew modestly by 4.5% y/y (offtakes at 418kt), while DAP registered a sharp 132% y/y spike (offtakes at 95kt), highlighting early procurement activity. However, cumulative 5MCY25 Urea and DAP sales still lag y/y by 31% and 34%, respectively, owing to weak agronomics and erosion in farmer incomes.

Urea Industry Volumetric Position							
Urea	May-25	May-24	Y/Y	Apr-25	M/M		
Opening Inventory	1,104	368	200%	820	35%		
Production	606	462	31%	570	6%		
Imports	-	-	-	-	-		
Off-take	418	400	5%	251	67%		
Closing inventory	1,316	425	210%	1,104	19%		


Source: NFDC & HMFS Research


Hefty Inventory May Cap Price Moves

Despite the monthly recovery in sales, inventory levels swelled further in May. Urea closing inventory stood at 1.32mnt, up 19% m/m, marking the highest level in eight years, as supply outpaced demand amid previous months' muted offtake. DAP inventory also climbed to 238kt, up 17% m/m, aided by 52kt of imports and lower-than-expected sales. This build-up in stock levels reflects a cautious underlying demand trend and may weigh on future pricing decisions.



UREA Market Share - 5MCY25







Seasonal Surge Lifts Offtake, Yet Surplus Signals Underlying Strain

Urea Volumes Recover; DAP Sales See FFC Dominance

Urea Offtakes

- **FFC** dispatched 207kt, down 10% y/y, but up 92% m/m.
- **EFERT** posted a strong rebound with 142kt, rising 84% y/y and 75% m/m, supported by competitive pricing and post-turnaround availability.
- **FATIMA** sold 25kt, up 79% y/y,

DAP Offtakes

- FFC led with ~68kt, a 1.2x y/y jump and a sharp 24% m/m increase.
- **EFERT** sold 14kt, up 6x y/y, though m/m volumes dipped 55%.
- **FATIMA** added 3.2kt, up 1.6x y/y.

Stocked for Season, But Risks Remain

With projected urea availability of 4.0mnt against expected Kharif demand of 3.16mnt, the sector appears comfortably stocked for the season. Similarly, DAP availability at 889kt should meet estimated demand of 804kt, assuming smooth import execution and uninterrupted gas supply to FFBL. That said, the elevated inventory levels and fragile farm economics warrant caution. While seasonality offers a near-term boost, sustainable demand will hinge on crop pricing recovery, irrigation flows, and government support continuity.

	May-25	May-24	Y/Y	Apr-25	M/M
Off-take (kt)					
Urea	418	400	5%	251	67%
DAP	95	41	135%	95	0%
Retail price (PKR/bag)					
Urea	4,476	4,840	-8%	4,499	-0.5%
DAP	12,606	11,553	9%	12,363	2%
Source: NFDC & HMFS Research	ch				



HABIBMETRO

DISCLAIMER

Financial Services

This research report is for information purposes only and does not constitute nor is it intended as an offer or solicitation for the purchase or sale of securities or other financial instruments. Neither the information contained in this research report, nor any future information made available with the subject matter contained herein will form the basis of any contract. Information and opinions contained herein have been compiled or arrived at by Habib Metropolitan Financial Services (HMFS) from publicly available information and sources that HMFS believed to be reliable. Whilst every care has been taken in preparing this research report, no research analyst, director, officer, employee, agent or adviser of any member of HMFS gives or makes any representation, warranty or undertaking, whether express or implied, and accepts no responsibility or liability as to the reliability, accuracy or completeness of the information set out in this research report. Any responsibility or liability for any information contained herein is expressly disclaimed. All information contained herein is subject to change at any time without notice. No member of HMFS has an obligation to update, modify or amend this research report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate, or if research on the subject company is withdrawn. Furthermore, past performance is not indicative of future results.

The investments and strategies discussed herein may not be suitable for all investors or any particular class of investor. Investors should make their own investment decisions using their own independent advisors as they believe necessary and based upon their specific financial situations and investment objectives when investing. Investors should consult their independent advisors if they have any doubts as to the applicability to their business or investment objectives of the information and the strategies discussed herein. This research report is being furnished to certain persons as permitted by applicable law, and accordingly may not be reproduced or circulated to any other person without the prior written consent of a member of HMFS. This research report may not be relied upon by any retail customers or person to whom this research report may not be provided by law. Unauthorized use or disclosure of this research report is strictly prohibited. Members of any issuers discussed herein, may engage in securities transactions in a manner inconsistent with the research contained in this research report and with respect to securities or financial instruments covered by this research report, may sell to or buy from customers on a principal basis and may serve or act as director, placement agent, advisor or lender, or make a market in, or may have been a manager or a co-manager of the most recent public offering in respect of any investments or issuers of such securities or financial instruments referenced in this research report or may perform any other investment banking or other services for, or solici investment banking or other business from any company mentioned in this research report. Investing in Pakistan involves a high degree of risk and many persons, physical and legal, may be restricted from dealing in the securities market of Pakistan. Investors should perform their own due diligence before investing. No part of the compensation of the authors of this research report. By accepting this research repo

HMFS and / or any of its affiliates, which operate outside Pakistan, do and seek to do business with the company(s) covered in this research document. Investors should consider this research report as only a single factor in making their investment decision. HMFS prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer/company prior to the publication of a research report containing such rating, recommendation or investment thesis. Furthermore, it is stated that the research analyst (s) or their close relatives have neither served as a director/officer in the past 3 years nor have received any compensation from the subject company in the past 12 months. Additionally, as per regulation 8(2)(i) of the Research Analyst Regulations, 2015, research analysts currently do not have a financial interest in the securities of the subject company aggregating more than 1% of the value of the company. The research analyst(s) also certifies that any spouse(s) or dependents (if relevant) do not hold a beneficial interest in the securities that are subject of this report.

HMFS endeavors to make all reasonable efforts to disseminate its publication to all eligible clients in a timely manner through either physical or electronic distribution such as mail, fax and/or email. Nevertheless, not all clients may receive the material at the same time.

HMFS Stock Ratings System

Investors should carefully read the definitions of all rating used within every research reports. In addition, research reports carry an analyst's independent view and investors should ensure careful reading of the entire research reports and not infer its contents from the rating ascribed by the analyst. Ratings should not be used or relied upon as investment advice. An investor's decision to buy, hold or sell a stock should depend on said individual's circumstances and other considerations. HMFS uses a three-tier rating system: i) Buy, ii) Hold and iii) Sell with our rating being based on total stock returns. A table presenting HMFS' rating definitions is given below:

Valuation Methodology

To arrive at our fair value estimates, HMFS uses different valuation methodologies including but not limited to:

 •Discounted cash flow (DCF, DDM)

 •Relative Valuation (P/E, P/B, P/S etc.)

 •Equity & Asset return based methodologies (EVA, Residual Income etc.

 •Equity & Reserve the methodologies (EVA, Residual Income etc.

 •Equity & Asset return based methodologies (EVA, Residual Income etc.

 •Equity & Asset return based methodologies (EVA, Residual Income etc.

 •Equity & Asset return based methodologies (EVA, Residual Income etc.

 •Equity & Asset return based methodologies (EVA, Residual Income etc.

 •Equity & Asset return based methodologies (EVA, Residual Income etc.

 •Equity & Asset return based methodologies (EVA, Residual Income etc.

 •Equity & Asset return based methodologies (EVA, Residual Income etc.

 •Equity & Asset return based methodologies (EVA, Residual Income etc.

 •Equity & Asset return based methodologies (EVA, Residual Income etc.

 •Equity & Asset return based methodologies (EVA, Residual Income etc.

 •Equity & Asset return based on both the Capital Gains return & the Dividend Yield & is exclusive of all applicable taxes



www.hmfs.com.pk

